FDA Warns California Compounder for Unapproved Drugs Following Patient Death

Drug Industry Daily
A A
Drug compounder ImprimisRx landed itself in hot water with the FDA for producing adulterated, misbranded and unapproved drug products at its Irvine, California facility, activity that prompted the FDA to issue the firm a warning letter.

To View This Article:

Login

Subscribe To Drug Industry Daily